284 related articles for article (PubMed ID: 31013390)
1. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.
Frost M; Bailey GL; Lintzeris N; Strang J; Dunlop A; Nunes EV; Jansen JB; Frey LC; Weber B; Haber P; Oosman S; Kim S; Tiberg F
Addiction; 2019 Aug; 114(8):1416-1426. PubMed ID: 31013390
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F
Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder.
Haasen C; Linden M; Tiberg F
J Subst Abuse Treat; 2017 Jul; 78():22-29. PubMed ID: 28554599
[TBL] [Abstract][Full Text] [Related]
5. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
[TBL] [Abstract][Full Text] [Related]
7. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
[TBL] [Abstract][Full Text] [Related]
8. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Lofwall MR; Walsh SL; Nunes EV; Bailey GL; Sigmon SC; Kampman KM; Frost M; Tiberg F; Linden M; Sheldon B; Oosman S; Peterson S; Chen M; Kim S
JAMA Intern Med; 2018 Jun; 178(6):764-773. PubMed ID: 29799968
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder.
Björnsson M; Acharya C; Strandgården K; Tiberg F
Clin Pharmacokinet; 2023 Oct; 62(10):1427-1443. PubMed ID: 37584841
[TBL] [Abstract][Full Text] [Related]
10. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.
Dunlop AJ; White B; Roberts J; Cretikos M; Attalla D; Ling R; Searles A; Mackson J; Doyle MF; McEntyre E; Attia J; Oldmeadow C; Howard MV; Murrell T; Haber PS; Lintzeris N
Addiction; 2022 Feb; 117(2):382-391. PubMed ID: 34184798
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder.
Walsh SL; Comer SD; Zdovc JA; Sarr C; Björnsson M; Strandgården K; Hjelmström P; Tiberg F
Neuropsychopharmacology; 2024 May; 49(6):1050-1057. PubMed ID: 38200140
[TBL] [Abstract][Full Text] [Related]
12. Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.
Andorn AC; Haight BR; Shinde S; Fudala PJ; Zhao Y; Heidbreder C; Learned SM; Fox NL; Nadipelli VR; Hassman D; Rutrick D
J Clin Psychopharmacol; 2020; 40(3):231-239. PubMed ID: 32282418
[TBL] [Abstract][Full Text] [Related]
13. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.
Farrell M; Shahbazi J; Chambers M; Byrne M; Gholami J; Zahra E; Grebely J; Lintzeris N; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Weiss R; Rodgers C; Cook J; Degenhardt L;
Int J Drug Policy; 2024 May; 127():104390. PubMed ID: 38522175
[TBL] [Abstract][Full Text] [Related]
14. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
17. Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.
Greenwald MK; Wiest KL; Haight BR; Laffont CM; Zhao Y
Harm Reduct J; 2023 Dec; 20(1):173. PubMed ID: 38042801
[TBL] [Abstract][Full Text] [Related]
18. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
Larance B; Degenhardt L; Grebely J; Nielsen S; Bruno R; Dietze P; Lancaster K; Larney S; Santo T; Shanahan M; Memedovic S; Ali R; Farrell M
Addiction; 2020 Jul; 115(7):1295-1305. PubMed ID: 31860767
[TBL] [Abstract][Full Text] [Related]
19. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
Gunderson EW; Hjelmström P; Sumner M;
Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
[TBL] [Abstract][Full Text] [Related]
20. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.
Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C
J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]